Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Spero Therapeutics is raising $39,999,985.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Sath Shukla played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Spero Therapeutics
Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients unmet needs with multi-drug resistant (MDR) bacterial infections. Speros lead product candidate, tebipenem HBr, is an oral carbapenem being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. Spero is also developing SPR720, its oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Speros third product candidate, SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections. We believe that our novel product candidates will have a meaningful impact on patient health and significant commercial applications for treating MDR infections in hospitals and community settings.

To learn more about Spero Therapeutics, visit http://www.sperotherapeutics.com/

Contact:
Sath Shukla, Chief Financial Officer
857-242-1600
sshukla@sperotherapeutics.com
https://www.linkedin.com/in/sath-shukla-32948a8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved